NEW YORK- Shares of Boston Scientific the developer of medical devices that are used in a range of interventional medical specialties reported Q3 net income of $190 million or 12 cents a share with revenue coming in at $1.9 billion. The company was quick to point out that net income would have been $296 million without restructuring and impairment charges. However, when examining their financial statements this does not appear to be true because the charges appear to be a regular occurrence as opposed to a one time charge. The company expects to earn adjusted profit of $0.63 and $0.66 but 0.77 to 0.81 loss per on a GAAP basis.
headerads
Tuesday, October 19, 2010
The Science Report (NYSE: BSX)
NEW YORK- Shares of Boston Scientific the developer of medical devices that are used in a range of interventional medical specialties reported Q3 net income of $190 million or 12 cents a share with revenue coming in at $1.9 billion. The company was quick to point out that net income would have been $296 million without restructuring and impairment charges. However, when examining their financial statements this does not appear to be true because the charges appear to be a regular occurrence as opposed to a one time charge. The company expects to earn adjusted profit of $0.63 and $0.66 but 0.77 to 0.81 loss per on a GAAP basis.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment